Experience with sevelamer in peritoneal dialysis;Experiencia con sevelamer en diálisis peritoneal

Nefrologia

Volumn 23, Issue 5, 2003, Pages 432-436

  Ortiz, A ^a,c   Rios F ^a   Melero, R ^a   Reyero, A ^a   Gazapo, R ^b   Casado, S ^a  

^a Nefrologia IdiPAZ   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c Unidad de Dialisis   (Spain)

Author keywords

Peritoneal dialysis; Phosphorus; Sevelamer

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM SALT; CARBON DIOXIDE; CHELATING AGENT; GAMMA GLUTAMYLTRANSFERASE; PARATHYROID HORMONE; SEVELAMER; EPOXIDE; POLYAMINE; POLYETHYLENE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PRACTICE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERPHOSPHOREMIA; HYPOCALCEMIA; MALE; NAUSEA; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRURITUS; TRIACYLGLYCEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1542441379     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Plone MA, Petersen JS, Rosenbaum DP, Burke SK: Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41: 517-23, 2002.
2. Braunlin W, Zhorov W, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville H, Holmes-Parley SR: bile acid binding to sevelamer HCl. Kidney Int 62: 611-9, 2002.
3. Wilkes BM, Reiner D, Kern M, Burke S: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 50: 381-6, 1998.
4. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51: 18-26, 1999.
5. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phospate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701, 1999.
6. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14: 2907-14, 1999.
7. Fournier A, Oprisiu R, Albu AT, Dungaciu M, El Esper N, Morniere P: The crossover comparative trial of calcium acetete versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients. Am J Kidney Dis 35: 1248-50, 2000.
8. Chertow GM, Burke SK, Raggi P: Treat to goal working group. Sevelamer attenuates the progression of coronay and aortic calcification in hemodialysis patients. Kidney Int 62: 245-52, 2002.
9. Paz Marco MP, Muray S, Betriu A, Graver L, Belart M, Fernández E: Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 92: 499-500, 2002.
10. Gallieni M, Cozzolino M, Brancaccio D: Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int 57: 1776-7, 2000.
11. Berlanga JR, Marrón B, Reyero A, Caramelo C, Ortiz A: Peritoneal dialysis retardation of progression of advanced renal failure. Perit Dial Int 22: 239-42, 2002.
12. Chertow GM, Plone M, Dillon MA, Burke SK, Slatopolsky E; Hyperparathyroidism and dialysis vintage. Clin Nephrol 54: 295-300, 2000.
13. Slatopolsky EA, Burke SK, Dillon MA: Renagel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Kidney Int 55: 299-307, 1999.
14. McIntyre CW, Patel V, Taylor GS, Fluck RJ: A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 17: 1643-8, 2002.
15. Knodel LC, Talbert RL: Adverse effects of hypolipidaemic drugs. Med Toxicol 2: 10-32, 1987.
16. Stanley TB, Jin DY, Lin PJ, Stafford DW: The propeptides of the vitamin D-dependent proteins possess different affinities for the vitamin K-dependent carboxylase. J Biol Chem 274: 16940-4, 1999.
17. Chertow GM, Dillon MA, Amin N, Burke SK: Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 10: 125-32, 2000.